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INTRODUCTION
More than forty years after its introduction, cytarabine remains one of the most effective agents for the treatment of acute myelogenous leukemia (AML) (1, 2) . According to current understanding, this agent enters leukemic cells on nucleoside transporters (3, 4) and is then phosphorylated to cytosine arabinoside triphosphate (5, 6) , which acts as a competitive inhibitor of replicative DNA polymerases (7) (8) (9) . In addition, once incorporated into DNA (9-11), cytarabine causes replication fork slowing (12). These events conspire to activate the replication checkpoint. A critical aspect of that checkpoint involves the phosphorylation and activation of checkpoint kinase 1 (Chk1), which stabilizes replication forks, activates DNA repair, and suppresses apoptosis (13) (14) (15) (16) (17) (18) .
We (19, 20) and others (21, 22) have demonstrated that cytarabine induces activation of the replication checkpoint and S phase arrest. Inhibition of Chk1 by 7-hydroxystaurosporine (UCN-01) enhances cytarabine-induced apoptosis in vitro (23) . Clinical trials combining UCN-01 with S-phase damaging agents have been problematic, however, because of the drug's long half-life (24,25) and its diverse toxicities that may reflect inhibition of a large number of kinases (26,27).
Depletion of Chk1 either by siRNA or by tanespimycin-induced release from heat shock protein 90 (Hsp90) and subsequent proteasomal degradation (28) also enhances the cytotoxicity of cytarabine in AML cell lines and primary AML specimens (20) . Building on these observations, we conducted a phase I trial to determine if cytarabine activates the S phase checkpoint and To extend these findings to the clinical setting, we have conducted a Phase I dose-escalation trial of SCH 900776 in combination with timed-sequential cytarabine in 24 adults with relapsed and refractory acute leukemias. In particular, patients were treated with cytarabine by continuous infusion on days 1-3 and 10-12, with SCH 900776 administered beginning 24 hours after the start of each cytarabine infusion to allow for checkpoint activation before administration of the CHK1 inhibitor (31).
Research. 
PATIENTS, MATERIALS AND METHODS
Patient Eligibility and Selection. Patients age 18 and older with pathologically confirmed, relapsed and refractory AML, acute lymphoblastic leukemia (ALL), or chronic myelogenous leukemia in accelerated phase (CML-AP) or blast crisis (CML-BC) were eligible provided that they had ECOG performance status 0-2, serum creatinine < 1.5x upper limit of normal (ULN), hepatic enzymes < 5x ULN, bilirubin < 1.5 mg/dl, and left ventricular ejection fraction (LVEF) > 45%. Patients were eligible if they had undergone no more than 4 prior courses of cytotoxic induction therapies.
Patients who had undergone allogeneic or autologous stem cell transplantation (SCT) and had relapsed or were refractory thereafter (i.e., had persistent leukemia) were eligible. Patients were not eligible if they had a peripheral blast count >50,000/mm Table 1) . The majority had AML that had not responded to the most recent therapy (refractory, 13/24, 54%), previous exposure to moderately high doses of cytarabine (15/24, 63%), and/or adverse genetic features (15/24, 63%: 12/24, 50%, adverse cytogenetics; 3/24, 13%, FLT-3-internal tandem duplication). In addition, 7/21 (33%) AML patients had received prior allogeneic SCT. Median time from SCT to relapse was 7 months (range 3-16).
Toxicities. Clinical Outcome. As presented in Table 3 and detailed in Table 4 Nonetheless, because many patients who are deemed refractory to cytarabine do not receive subsequent cytarabine or, alternatively, receive higher doses of cytarabine that lead to responses in a small subset of such patients, we cannot exclude the possibility that some or all of the responders might have responded to timed sequential cytarabine without SCH 900776.
Moreover, the small sample size and heterogeneous nature of this patient population preclude any ability to draw accurate conclusions regarding additive or synergistic clinical effects of adding SCH 900776 to cytarabine, and we do not know if the overall response rate seen in our study is different from that seen with high dose cytarabine alone. To address these questions will require a larger study with randomization between the SCH 900776/cytarabine combination vs. 
